Contributors: IMRB - "Neuropsychiatrie translationnelle" Créteil (U955 Inserm - UPEC); Institut Mondor de Recherche Biomédicale (IMRB); Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); CHU Henri Mondor Créteil; Fondation FondaMental Créteil; Institut de pharmacologie moléculaire et cellulaire (IPMC); Université Nice Sophia Antipolis (1965 - 2019) (UNS)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UniCA); CHU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Département de psychiatrie adulte; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Hôpital La Colombière; Centre hospitalier Charles Perrens Bordeaux; Université de Bordeaux (UB); Nutrition et Neurobiologie intégrée (NutriNeuro); Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE); Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS); Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg; Les Hôpitaux Universitaires de Strasbourg (HUS)-Les Hôpitaux Universitaires de Strasbourg (HUS); Plateforme de Ressources Biologiques Henri Mondor AP-HP, Créteil (PRB); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Henri Mondor Créteil; CHU Clermont-Ferrand; Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Hôpital Louis Mourier - AP-HP Colombes; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Centre Référent de Réhabilitation Psychosociale CH Alpes Isère; Centre Hospitalier Alpes Isère; Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS); Aix Marseille Université (AMU); Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); Institut de Neurosciences cognitives et intégratives d'Aquitaine (INCIA); Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1 (UB)-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS); Centre de recherche en épidémiologie et santé des populations (CESP); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay; Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ); We thank all the patients who participated in the study. The work wasfunded by grants from the International IF foundation (RT), AgenceNationale pour la Recherche (I-GIVE ANR-13-SAMA-0004-01) (RT),Fondation de France (NG), Fondation FondaMental and the UniversiteC^ote d’Azur (SB). Support from the European program EraNet Micro-Schiz and PerMedSchiZ, the LABEX BioPSY and the LABEX SIGNALIFE(ANR-11-LABX-0028-01), the FHU ADAPT and the FHU OncoAge aregratefully acknowledged; Collaborators FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Groups: F Berna, E Haffen, M Leboyer, P M Llorca, F Schürhoff, V Barteau, S Bensalem, O Godin, H Laouamri, K Souryis, M Leboyer, I Offerlin-Meyer, B Pignon, F Schürhoff, A Szöke, B Aouizerate, A Deloge, D Misdrahi, E Vilà, O Blanc, I Chéreau, H Denizot, R M Honciuc, D Lacelle, P M Llorca, S Pires, C Dubertret, J Mallet, C Portalier, J Dubreucq, C Fluttaz, F Gabayet, C Roman, G Chesnoy-Servanin, T D'Amato, J M Dorey, R Rey, A Vehier, C Lançon, C Faget, E Metairie, P Peri, F Vaillant, L Boyer, G Fond, F Berna, P Vidailhet, A Zinetti-Bertschy, D Capdevielle, H Yazbek, S Esselin, M Jarroir, C Passerieux, M Urbach; ANR-13-SAMA-0004,I-GIVE,Immuno-Génétique, Inflammation, retro-Virus, Environnement : de l'étiopathogénie des troubles psychotiques aux modèles animaux(2013); ANR-11-LABX-0028,SIGNALIFE,Réseau d'Innovation sur les Voies de Signalisation en Sciences de la Vie(2011)
نبذة مختصرة : International audience ; Background: Metabolic syndrome (MetS) is a highly prevalent and harmful medical disorder often comorbid with psychosis where it can contribute to cardiovascular complications. As immune dysfunction is a key shared component of both MetS and schizophrenia (SZ), this study investigated the relationship between immune alterations and MetS in patients with SZ, whilst controlling the impact of confounding clinical characteristics including psychiatric symptoms and comorbidities, history of childhood maltreatment and psychotropic treatments.Method: A total of 310 patients meeting DSM-IV criteria for SZ or schizoaffective disorders (SZA), with or without MetS, were systematically assessed and included in the FondaMental Advanced Centers of Expertise for Schizophrenia (FACE-SZ) cohort. Detailed clinical characteristics of patients, including psychotic symptomatology, psychiatric comorbidities and history of childhood maltreatment were recorded and the serum levels of 18 cytokines were measured. A penalized regression method was performed to analyze associations between inflammation and MetS, whilst controlling for confounding factors.ResultsOf the total sample, 25% of patients had MetS. Eight cytokines were above the lower limit of detection (LLOD) in more than 90% of the samples and retained in downstream analysis. Using a conservative Variable Inclusion Probability (VIP) of 75%, we found that elevated levels of interleukin (IL)-6, IL-7, IL-12/23 p40 and IL-16 and lower levels of tumor necrosis factor (TNF)-α were associated with MetS. As for clinical variables, age, sex, body mass index (BMI), diagnosis of SZ (not SZA), age at the first episode of psychosis (FEP), alcohol abuse, current tobacco smoking, and treatment with antidepressants and anxiolytics were all associated with MetS.Conclusion: We have identified five cytokines associated with MetS in SZ suggesting that patients with psychotic disorders and MetS are characterized by a specific “immuno-metabolic” profile. This may help to ...
Processing Request
No Comments.